Hi IHS
Another aspect which I think makes PTX stand out as an investment compared with other cancer biotechs is its business model.
Steve Yatomi-Clarke likes to refer to this as a “shovels to the goldrush” model.
Other than its own internal cancer programs (currently 2 clinical-stage targeted therapies and 3 preclinical-stage CAR-T therapies), PTX has three separate platforms available for outlicensing.
The three platforms can be used separately, or combined.
- The OMNICAR platform, which other companies can license to pursue their own targets.
- CellPryme- M, which can be easily incorporated into the cell-manufacturing process of any other CAR-T company. It optimises the cells to be used in treatment so they are more persistent. It can be also be used with existing suboptimal CAR-T therapies.
- CellPryme-A, an adjunct therapy which is administered alongside a patient’s CAR-T therapy. It improves tumour killing and host survival of the CAR-T therapy when used in solid cancers and these benefits can be further maximised if CellPryme-M is also used.
PTX owns the IP for both CellPryme-M and CellPryme-A.
- Forums
- ASX - By Stock
- PTX
- Ann: Trading Halt
Ann: Trading Halt, page-30
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
3.9¢ |
Change
0.001(1.30%) |
Mkt cap ! $31.40M |
Open | High | Low | Value | Volume |
3.9¢ | 3.9¢ | 3.7¢ | $23.65K | 615.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 564695 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.0¢ | 26186 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 564695 | 0.038 |
10 | 616067 | 0.037 |
8 | 688946 | 0.036 |
7 | 571733 | 0.035 |
1 | 40000 | 0.034 |
Price($) | Vol. | No. |
---|---|---|
0.040 | 26186 | 2 |
0.042 | 200000 | 1 |
0.044 | 286522 | 2 |
0.045 | 509634 | 5 |
0.046 | 298002 | 2 |
Last trade - 15.59pm 03/07/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
TON
TRITON MINERALS LTD
Adrian Costello, Executive Director
Adrian Costello
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online